Pearl Steinzor

For patients with aspirin-exacerbated respiratory disease (AERD), omalizumab significantly reduced their symptoms, according to one study.

Individuals with severe type 2 asthma and chronic rhinosinusitis with nasal polyps may benefit from the biologic treatment, dupilumab.

Judy Alberto, MHA, RPh, BCOP, director of clinical initiatives at the Community Oncology Alliance, discusses the importance of making sure oncology practices are educated about their value-based enterprise exception when mailing patients their cancer medications.

Debra Patt, MD, PhD, MBA, executive vice president at Texas Oncology, explains the small potential risk of breast cancer associated with hormonal birth control.

Shiela Plasencia, director of practice support at the Community Oncology Alliance, discusses the benefits of collecting social determinants of health data for both the patient and provider.

Sleep and genetics play individual roles in increasing a person’s risk for asthma, but their combination also heightens that risk.

Physicians may be able to better identify patients with chronic cough using the combination of 2 coughing tests.

Amy Valley, vice president for clinical strategy and technology solutions at Cardinal Health, weighs both the benefits and potential risks of physicians using artificial intelligence technology in their oncology practices.

Kathy Oubre, MS, CEO of Pontchartrain Cancer Center, discusses the use of biosimilars and how pharmacy benefit managers (PBMs) as well as payers have challenged the biosimilar market.

People with chronic obstructive pulmonary disease (COPD) are at increased risk of long-term hearing loss, researchers find.

Debra Patt, MD, PhD, MBA, executive vice president at Texas Oncology, discusses her recent testimony to the US Senate on a case in which prior authorization caused a 6-week wait for a consult.

Nicolas Ferreyros, managing director at Community Oncology Alliance (COA), discusses the recent Senate commerce hearing on pharmacy benefit managers (PBMs), which brought bipartisan attention and energy towards addressing the concerns related to PBMs in Washington.

Researchers compared the effectiveness of 3 biologics for moderate to severe asthma in an observational study and found superior improvement with dupilumab.

Children born preterm are more likely to have respiratory symptoms at least up to middle age, according to one study.

Using gene enrichment analysis, a genome-wide association study (GWAS) identified a strong association with chronic obstructive pulmonary disease (COPD) and multiple ancestry groups.

Mike Lattanzi, MD, genitourinary medical oncologist, Texas Oncology, discusses the importance of keeping pace with precision oncology options as rates for prostate cancer increase.

The Assessment of Burden Chronic Conditions (ABCC) tool adds validity when measuring burden of disease among people with chronic conditions, according to one study.

A study including data from more than 2 million patients highlights gender, health insurance, and income disparities in patients receiving extracorporeal membrane oxygenation (ECMO) while hospitalized for severe respiratory illness.

Rates of asthma diagnoses declined at the beginning at the pandemic compared with rates of new diagnoses in the previous 3 years, according to one study.

Biomarker testing is a key tool in lung cancer treatment, and Kentucky recently passed a law requiring payers to cover biomarker tests with the intention to address high rates of lung cancer in the state.

Abdominal and general obesity were associated with adverse respiratory symptoms, with some independent factors identified in women, but not in men.

Mike Lattanzi, MD, genitourinary medical oncologist, Texas Oncology, discusses recent findings from studies he participated in on targeted therapies for muscle-invasive bladder cancer.

Pollen may contribute to an increased risk of asthma attacks and asthma-related emergency visits, according to one study.

Spirometry could aid physicians in identifying patients with chronic obstructive pulmonary disease (COPD) that are at high risk of cardiovascular disease, a study finds.

Kathy Oubre, MS, CEO of Pontchartrain Cancer Center, discusses patient advocacy and legislative issues that will continue to define the future of community oncology.

Research suggests allergic diseases may increase risk of osteoarthritis (OA), for which there is currently no effective cure.

Racial and ethnic disparities are apparent among Black patients with pulmonary fibrosis (PF), including earlier onset of death, according to a recent study.

Davey B. Daniel, MD, chief medical officer at OneOncology, shares his insights on health equity practices, as well as the importance of developing clinical models within community oncology.

Debra Patt, MD, PhD, MBA, executive vice president at Texas Oncology, discusses financial drivers affecting community oncology as well as new advances within cancer care that allow it to be treated as a chronic disease.

Minority patients with skin diseases such as psoriasis often experience racial and ethnic barriers to care, a recent review found.